Researchers studying ketamine as suicide prevention drug

March 27, 2013 by Bob Shepard, University of Alabama at Birmingham

(Medical Xpress)—University of Alabama at Birmingham (UAB) researchers think ketamine, an anesthesia medication in use since the 1970s, might be a valuable tool in treating severe depression and reducing suicidal urges; they have launched two studies to explore the possibility. One of the studies, ketamine is administered to suicidal patients in the UAB Hospital emergency department (ED), is the only such trial actually being conducted in an ED in the nation.

"There is a growing body of evidence that indicates that lower doses of ketamine can reduce suicidal feelings and relieve symptoms of in a very short period of time, as little as a few hours, which makes it an extremely attractive candidate for treating acute depression," said Richard Shelton, M.D., professor in the Department of Psychiatry and Behavioral Neurobiology and lead investigator on the studies.

Shelton said ketamine appears to work on depression by blocking a neurotransmitter called glutamate from binding to the on neurons. Too much glutamate on an NMDA receptor leads to the opening of a channel, releasing too much calcium downstream. This then affects a , (BDNF), which increases connections between neurons in the brain. These connections help the brain regulate emotions better.

In the trial, patients presenting to the ED with suicidal thoughts can be enrolled in the ketamine trial. The drug is administered via infusion, which takes about five minutes.

"We have seen a decrease in depression scores and suicide scores, sometimes within 15 minutes after giving ketamine," said Cheryl McCullumsmith, M.D., Ph.D., assistant professor and director of hospital psychiatry. "The antidepressants commonly used to treat depression and suicidal thoughts take weeks or months to begin to show positive effects. When a patient is actively suicidal, we don't have that much time."

McCullumsmith said patients entered in the ketamine trial at the ED are admitted to the psychiatric inpatient unit for observation.

"We are attempting to determine just how quickly the drug produces a beneficial result, as well as how long that result lasts," McCullumsmith said.

Shelton said a second trial, sponsored by Janssen Research & Development, LLC., is a multi-site trial of patients with severe depression and possible who are seen in an outpatient setting. Patients receive two or three infusions of ketamine or placebo each week for four-to-six weeks. Patients who do not benefit from study treatment after the first two weeks are offered two weeks of treatment with ketamine without the chance of placebo.

"We're interested in knowing how long each infusion will sustain the beneficial effect," said Shelton. "Ketamine does not appear to be curative, and we have a lot of work to do to see if it might be a useful drug for depression and suicide prevention on a long-term, regular-use basis."

A third trial underway at UAB is testing a compound called Glyx-13, produced by Naurex, Inc. Glyx-13 may produce similar results as ketamine by blocking an amino acid called glycine, which works in tandem with glutamate. Glycine regulates glutamate signaling, so it is like an added layer of fine-tuning. When glycine and glutamate bind to NMDA together, the calcium opens widely. Blocking glutamate with ketamine can reduce the release of calcium. Blocking glycine with Glyx-13 may achieve the same result, but more subtly and with fewer side effects.

"Glyx-13 may prove to be a more promising candidate than ketamine in terms of potential side effects," said Shelton. "Glyx-13 is being evaluated with just one infusion per week."

Ketamine, when used in anesthesia, has some side effects, including hallucinations and psychotic symptoms. It has also been a drug of abuse, known on the street as Special K. Shelton said the dose used in the trials is much lower, and given over a longer period. observed thus far in the ketamine trials have been minimal, he said.

Explore further: Ketamine improved bipolar depression within minutes

More information: UAB is enrolling patients in the outpatient trials of ketamine and Glyx-13. Male and female patients ages 19-64 with a diagnosis of depression, who have failed two drug regimens for depression, are candidates for the trials. Total time involved in the studies, with treatment and follow-up, is about 13 weeks. Individuals interested in more information can contact the study coordinator at 205-975-2911 or hammond@uab.edu.

Related Stories

Ketamine improved bipolar depression within minutes

May 30, 2012
Bipolar disorder is a serious and debilitating condition where individuals experience severe swings in mood between mania and depression. The episodes of low or elevated mood can last days or months, and the risk of suicide ...

Experimental agent briefly eases depression rapidly in test: Works in brain like ketamine, with fewer side effects

December 11, 2012
(Medical Xpress)—A drug that works through the same brain mechanism as the fast-acting antidepressant ketamine briefly improved treatment-resistant patients' depression symptoms in minutes, with minimal untoward side effects, ...

Ketamine helps see how the brain works in clinical depression

June 16, 2011
(Medical Xpress) -- In a new study published in Nature, Lisa Monteggia from the University of Texas Southwestern Medical Center looks at how the drug ketamine, typically used as an anesthetic or a popular recreational drug ...

'Special K' could relieve depression

June 7, 2012
(Medical Xpress) -- Recreational drug and anaesthetic, ketamine, is being trialled in people with severe depression and is providing almost instant relief from symptoms, offering fresh hope of a quick new way to manage the ...

Scientists explain how ketamine vanquishes depression within hours

October 4, 2012
(Medical Xpress)—Many chronically depressed and treatment-resistant patients experience immediate relief from symptoms after taking small amounts of the drug ketamine. For a decade, scientists have been trying to explain ...

Recommended for you

Priming can negate stressful aspects of negative sporting environments, study finds

January 23, 2018
The scene is ubiquitous in sports: A coach yells at players, creating an environment where winning is the sole focus and mistakes are punished. New research from the University of Kansas shows that when participants find ...

Curcumin improves memory and mood, study says

January 23, 2018
Lovers of Indian food, give yourselves a second helping: Daily consumption of a certain form of curcumin—the substance that gives Indian curry its bright color—improved memory and mood in people with mild, age-related ...

Social and emotional skills linked to better student learning

January 23, 2018
Students with well-developed and adaptive social and emotional behaviours are most likely to excel in school, according to UNSW researchers in educational psychology.

People with prosthetic arms less affected by common illusion

January 22, 2018
People with prosthetic arms or hands do not experience the "size-weight illusion" as strongly as other people, new research shows.

Intensive behavior therapy no better than conventional support in treating teenagers with antisocial behavior

January 19, 2018
Research led by UCL has found that intensive and costly multisystemic therapy is no better than conventional therapy in treating teenagers with moderate to severe antisocial behaviour.

Babies' babbling betters brains, language

January 18, 2018
Babies are adept at getting what they need - including an education. New research shows that babies organize mothers' verbal responses, which promotes more effective language instruction, and infant babbling is the key.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.